Sinusitis Treatment Market Size, Share and Trends 2024 to 2034

Sinusitis Treatment Market Size and Forecast 2024 to 2034

The global sinusitis treatment market size is calculated at USD 2.4 billion in 2024 and is anticipated to reach around USD 4.22 billion by 2034, expanding at a CAGR of 5.82% from 2024 to 2034. Increasing prevalence of the condition is the key factor driving the growth of the market. Also, the growing need for timely diagnosis, along with the growing demand for better treatment options, is expected to fuel market growth shortly.

Sinusitis Treatment Market Key Takeaways

• North America dominated the sinusitis treatment market in 2023.
• Asia Pacific is expected to grow at the fastest rate over the projected period.
• By type, the acute sinusitis segment dominated the market in 2023.
• By type, the chronic segment has been growing significantly over the forecast period.
• By route of administration, the nasal segment led the market in 2023 by holding the largest market share.
• By route of administration, the oral segment held a significant share in 2023.
• By treatment, the analgesic segment dominated the sinusitis treatment market in 2023.

Market Overview

Sinusitis is a disease condition that has adverse effects on the majority of the population in the world. The condition can be triggered by environmental factors like smoke, animal dander, dust, and polluted air. Sinusitis is also distinguished by inflammation of the sinus layer caused by irritants, viruses, allergens, bacteria, and microbes. The infected patient complains of facial pain, congestion, postnasal drip, and headache. Viral sinusitis is easier to treat, and patients can recover quickly without antibiotics.

Global Lung Cancer Statistics (2022)

Sinusitis Treatment Market Growth Factors

• Factors such as unhealthy lifestyles and habits like smoking are expected to increase the incidence of sinus disorders, thereby boosting market growth.
• Increasing demand for fast relief treatment options for sinuses can propel market growth further.
• Growing recommendations from regulatory bodies for approval of the advanced drug used in the treatment of sinuses will likely contribute to market expansion soon.

Impact of AI on the Sinusitis Treatment Market

The integration of artificial intelligence (AI) is substantially impacting the market. AI-generated diagnostics and treatment options are improving the precision and efficiency of patient management. Furthermore, AI is optimizing workflow efficiencies, decreasing the time needed for diagnosis and customized treatment approaches. The rising adoption of AI in medical settings is expected to fuel the opportunities and advancements in the sinusitis treatment sector.

• In July 2024, SoundHealth, a medical technology company that emphasized harnessing AI for better health outcomes, unveiled SONU, the world's first FDA-cleared AI-powered wearable for treating moderate to severe nasal congestion.
• In January 2022, Acclarent Inc., a leader in making minimally invasive ear, nose, and throat (ENT) technologies, launched its first-ever AI-powered ENT technology, created to simplify surgical planning and offer real-time feedback during ENT navigation procedures.

Market Scope

Market Dynamics

Driver

Increasing demand for nasal sprays

Advanced nasal spray designs are a fact-pacing phenomenon in the market. Innovators are suggesting that investors must go beyond drug advancements and emphasize various ways to deliver it in the cavities of sinus patients. Additionally, key players are taking advantage of such advances to develop new innovative devices that enable individuals to treat themselves in the comfort of their homes and lessen the symptoms of sinusitis in the primary stages.

• In September 2024, Mucinex, a Reckitt brand and the #1 most trusted brand by doctors for cough and cold symptoms, introduced Mucinex Sinus Saline Nasal Spray designed to treat sinus-related symptoms.
• In September 2022, Ryaltris's new nasal spray was approved by the US Food and Drug Administration for adults and children aged 12 years and older and has an onset of action of within 15 minutes for nasal symptoms, according to a company press release.

Restraint

Lack of skilled medical professionals

The lack of well-trained medical professionals who are unable to diagnose and treat patients with proper treatments can hinder the growth of the sinusitis treatment market. However, the huge expenditure related to the treatment of sinusitis can also negatively impact the market growth because it includes high-end drug types like antihistamines and corticosteroids.

Opportunity

Increase in prevalence of rhinosinusitis

The incidence of rhinosinusitis is increasing rapidly across the globe. Acute rhinosinusitis lasts less than 4 weeks, and subacute rhinosinusitis lasts approximately 12 weeks. Furthermore, Patients suffering from acute rhinosinusitis witness more than four acute episodes that last for at least f 7 days. The symptoms of chronic rhinosinusitis can last for more than 12 weeks. The extensive range of impact created by rhinosinusitis constrains individuals from doing mundane tasks and suggests a high time for searching for a better life.

• In April 2024, OM1 and Medtronic Partnered on PROPEL to study and assess long-term outcomes for patients with chronic Rhinosinusitis. The research is meant to prove that PROPEL devices are associated with decreased HCRU and surgical revisions after sinus surgery.

Type Insights

The acute sinusitis segment dominated the sinusitis treatment market in 2023. The dominance of the segment can be attributed to the increasing introduction of biologics like omalizumab, etc. Key firms are continuously increasing their expenditure on innovation and marketing, which in turn results in a rising focus on process efficiency and cost management. Additionally, disease symptoms like Hay fever or common cold caused by allergies can be treated with biological treatments.

The chronic segment is expected to grow significantly in the sinusitis treatment market over the forecast period. The growth of the segment can be linked to the rising prevalence of chronic Hay sinusitis in the majority of the population across the globe. Chronic sinusitis is caused by bacteria growing in the sinuses and can last for more than three months. Furthermore, conditions like allergies, asthma, and cystic fibrosis can block the nasal airways, which can lead to the occurrence of chronic sinusitis.

Route of Administration Insights

The nasal segment led the sinusitis treatment market in 2023 by holding the largest market share. The dominance of the segment is due to the drug administration through the nasal root, which absorbs more drugs to exert local or systemic therapeutic effects. However, the nasal route has benefits for being non-invasive with rapid absorption, low infection, and brain targeting properties, which can drive the segment growth further.

• In October 2024, Aero Pump and Resyca will announce their partnership in the launch of the innovative Ultra Soft Nasal Pump Spray. Available for immediate licensing, this co-developed system represents a new frontier in nasal drug delivery, providing improved delivery efficiency, accuracy, and comfort for users.

The oral segment held a significant share of the sinusitis treatment market in 2023. This is because Oral administration is convenient and cost-effective. This route is the most commonly used drug administration route. The main site of drug absorption is generally the small intestine. Furthermore, the oral route offers a non-invasive, safer, and simpler way to administer medications for all types of diseases, including sinusitis. Drugs taken by oral routes can also show good patient compliance and response to the medications.

Treatment Insights

In 2023, the analgesic segment dominated the sinusitis treatment market by holding the share. The dominance of the segment can be credited to the increasing consumption of analgesics, which relieve the pain caused by pressure buildup in the sinus cavities. Also, analgesics and other pain relievers can help lessen fever and allergic conditions. Analgesics, such as ibuprofen, acetaminophen, and aspirin, can help relieve sinus pain and show the least side effects.

Regional Insights

North America dominated the sinusitis treatment market in 2023. The dominance of the region can be attributed to the increasing incidence of rhinosinusitis. Furthermore, rising pervasiveness of viral and bacterial infections. Also, major players in the market are focusing on developing advanced drug products for sinusitis because of ongoing innovations and advanced technology.

• In May 2023, the supplemental new drug application (NDA) submitted by the company Optinose for the approval of XHANCE, a treatment for chronic rhinosinusitis, was accepted for review by the U.S. Food and Drug Administration (FDA).

Asia Pacific region is expected to grow at the fastest rate over the projected period. The growth of the region can be driven by the high prevalence of sinusitis. However, the developing countries in the region, such as India and China, have the world's worst air quality, which can lead to a rapid surge in respiratory disorders along with the growth in industrialization.

Sinusitis Treatment Market Companies

• Abbott Laboratories Inc
• Bayer AG
• GSK plc
• Fresenius Kabi AG
• OptiNose US, Inc
• Dr. Reddys Laboratories Ltd.
• Cipla Inc.
• Stryker Corporation.
• Medtronic plc.

Recent Developments

• In May 2023, the well-known healthcare marketplace Zocdoc announced that it will now offer urgent care. With this advancement, patients will be able to easily find and book online and in-person treatments for more than two hundred specialties and more than 12,000 insurance kinds.
• In February 2022, Olympus, a company that creates and distributes ground-breaking solutions for medical and surgical procedures, announced that its CELERISTM single-use sinus debride system has been approved by the FDA and will soon be available for purchase.
• In May 2022, Delent Medical gets additional patent protection for its sinus leave balloon device, which also safeguards the company's proprietary device and strategic balloon sinus dilatation system for the treatment of chronic sinusitis. 
• In May 2022, Medtronic completed the acquisition of Intersect ENT to expand its ear, nose, and throat (ENT) division with new products utilized in sinus treatment. 
• In July 2022, high-performance, single-use endoscope producer Zsquare received an FDA 510K clearance to market its first product, the Zsquare ENT-Flex Rhinolaryngoscope. Zsquare plans to bring research to the U.S. 

Segments Covered in The Report

By Type

• Chronic Sinusitis
• Acute Sinusitis
• Sub-Acute Sinusitis

By Route of Administration

• Nasal
• Oral
• Injectable
• Topical

By Treatment

• Antibiotic
• Analgesic
• Anti-inflammatory
• Expectorants

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa